FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

· · · · · · · · · · · · · · · · · · ·	
gton, D.C. 20549	OMD A

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

	Check this box if no longer subject to
\neg	Section 16. Form 4 or Form 5
J	obligations may continue. See
	Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

Name and Address of Reporting Person Sukhatme Mayukh				2. Issuer Name and Ticker or Trading Symbol Roivant Sciences Ltd. [ROIV]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
/L aat)	/[-i-nt\	(Middle)										X	Officer (g below)	ive title		Other (sp below)	ecify
(Last) (First) (Middle) C/O ROIVANT SCIENCES LTD.					3. Date of Earliest Transaction (Month/Day/Year) 04/20/2022								See Remarks					
11-12 ST. JAMES'S SQUARE, STE 1, 3RD FL																		
(Street) LONDON X0 SW1Y 4LB					4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(5	State)	(Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Trans Date (Month/l				Date	2A. Deemed Execution Da if any (Month/Day/N		Date,	ate, Transacti Code (Ins					or 5. Amount Securities Beneficiall Following Reported		y Owned (D) or		r Indirect Estr. 4)	7. Nature of Indirect Beneficial Ownership
				Code V Amount (A) or P			ice	Transaction(s) (Instr. 3 and 4)				nstr. 4)						
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		saction Derivative			6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amour Securities Underly Derivative Securit (Instr. 3 and 4)			ying Derivative		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	Amour Numbe Shares	r of		(Instr. 4)			
Stock Option (Right to Buy)	\$3.85	04/20/2022		A		16,523,184		(1)	0	4/19/2032	Common Shares	16,52	3,184	\$0.00	16,523	,184	D	

Explanation of Responses:

1. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

Remarks:

Pres & Chief Investment Officer

By: /s/ Jo Chen, as Attorney-in-Fact for Mayukh Sukhatme

04/22/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.